Carcinoma in situ of endometrium
ICD-10 D07.0 is a billable code used to indicate a diagnosis of carcinoma in situ of endometrium.
Carcinoma in situ of the endometrium refers to a localized form of cancer where abnormal cells are found in the lining of the uterus (endometrium) but have not invaded deeper tissues or spread to other parts of the body. This condition is often asymptomatic and may be discovered incidentally during routine gynecological examinations or imaging studies. Risk factors include age, obesity, prolonged estrogen exposure, and a history of endometrial hyperplasia. Surveillance protocols typically involve regular pelvic examinations, transvaginal ultrasounds, and endometrial biopsies to monitor for progression to invasive cancer. The prognosis for carcinoma in situ is generally favorable, with a high rate of successful treatment when detected early. However, there is a risk of progression to invasive carcinoma, particularly in patients with underlying risk factors. Therefore, close monitoring and timely intervention are crucial to prevent disease advancement.
Detailed pathology reports, imaging studies, and treatment plans.
Routine screenings, abnormal uterine bleeding, and follow-up after biopsy.
Ensure accurate staging and grading of the carcinoma in situ.
Comprehensive treatment records, including surgical notes and chemotherapy regimens.
Management of patients post-diagnosis and during surveillance.
Coordination with gynecologists for multidisciplinary care.
Performed for treatment of carcinoma in situ when indicated.
Operative report detailing the procedure and findings.
Ensure coordination between gynecology and oncology for comprehensive care.
Carcinoma in situ indicates that cancerous cells are present but have not invaded surrounding tissues. Early detection and treatment are crucial to prevent progression to invasive cancer.
